BioVex - Top 20 Biotech VC Deals of 2009

Company: BioVex Group
Based: Woburn, MA
Amount: $70 million

Investors: Morningside Venture, Ventech, MVM Life Science Partners, Sectoral Asset Management and Ysios Capital Partners

Scoop: Following strong data from a Phase II trial of OncoVex, BioVex added $30 million more to its coffers, bringing its total take for the year to a whopping $70 million. OncoVex attaches a virus to a therapy designed to spur the immune system, essentially dispatching tumor-killers on a search and destroy mission.

The $70 million should be enough to see BioVex through Phase III trials of the program and give the company time to work on a licensing deal for its drug. BioVex was a Fierce 15 company in both 2005 and 2009.

Related Articles:
BioVex - 2009 Fierce 15
BioVex - 2005 Fierce 15 Revisited
BioVex CEO upbeat on OncoVex data, hints at a deal
BioVex raises $40M for Phase III work